Opinion
Video
Exploring Toxicities for Second Line Treatments in mCRC
The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.
- Briefly discuss common AEs for patients treated with 2L biomarker-directed therapy for mCRC.
- What similarities and differences can be observed based on specific clinically actionable targets?
- What strategies have you explored to mitigate and manage those events?
- Dr Marshall: Based on the following data updates presented in mCRC, how does this impact the future treatment landscape in the second line setting?
Related Videos
Related Content
